Aft Pharmaceuticals Ltd
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, … Read more
Aft Pharmaceuticals Ltd (AFP) - Total Assets
Latest total assets as of September 2025: AU$170.24 Million AUD
Based on the latest financial reports, Aft Pharmaceuticals Ltd (AFP) holds total assets worth AU$170.24 Million AUD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aft Pharmaceuticals Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Aft Pharmaceuticals Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aft Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Aft Pharmaceuticals Ltd's total assets of AU$170.24 Million consist of 63.8% current assets and 36.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 6.5% |
| Accounts Receivable | AU$43.20 Million | 25.4% |
| Inventory | AU$48.48 Million | 28.6% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$58.22 Million | 34.3% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Aft Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aft Pharmaceuticals Ltd's current assets represent 63.8% of total assets in 2025, a decrease from 93.1% in 2013.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, up from 4.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 4.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 34.3% of total assets.
Aft Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Aft Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Aft Pharmaceuticals Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Aft Pharmaceuticals Ltd generates 1.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Aft Pharmaceuticals Ltd generates $7.04 in net profit.
Aft Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 2.72 | 2.26 |
| Quick Ratio | 0.69 | 1.22 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$35.92 Million | AU$ 54.86 Million | AU$ 32.60 Million |
Aft Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Aft Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.78 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | AU$169.81 Million |
| Market Capitalization | $53.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aft Pharmaceuticals Ltd's assets below their book value (0.32 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Aft Pharmaceuticals Ltd's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Aft Pharmaceuticals Ltd (2013–2025)
The table below shows the annual total assets of Aft Pharmaceuticals Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | AU$169.81 Million | +2.76% |
| 2024-03-31 | AU$165.26 Million | +11.61% |
| 2023-03-31 | AU$148.06 Million | +16.29% |
| 2022-03-31 | AU$127.32 Million | +21.11% |
| 2021-03-31 | AU$105.13 Million | +20.77% |
| 2020-03-31 | AU$87.05 Million | +36.88% |
| 2019-03-31 | AU$63.59 Million | +12.35% |
| 2018-03-31 | AU$56.60 Million | -2.95% |
| 2017-03-31 | AU$58.33 Million | -10.69% |
| 2016-03-31 | AU$65.30 Million | +96.62% |
| 2015-03-31 | AU$33.21 Million | +30.42% |
| 2014-03-31 | AU$25.47 Million | +14.48% |
| 2013-03-31 | AU$22.25 Million | -- |